ALL

Allstate

$253.71

+0.76%
Sep 11, 2026
Bobby Quantitative Model
The Allstate Corporation is one of the largest U.S. property-casualty insurers, with personal auto representing its largest revenue line alongside homeowners and other insurance products sold primarily through roughly 6,000 exclusive agents across North America. The company occupies a top-tier competitive position in a consolidated industry dominated by a handful of national carriers, and its scale, brand recognition, and exclusive-agent distribution model distinguish it from direct-to-consumer disruptors and regional underwriters. The current investor narrative centers on a powerful earnings recovery driven by sharply lower catastrophe losses and disciplined auto rate increases, with recent commentary highlighting a 'quiet catastrophe year' that could power a strong Q2 and continued policy growth. At the same time, the stock's sharp multi-month rally has shifted the debate toward valuation and whether the margin expansion cycle is already priced in, a tension reflected in the mixed analyst ratings and the recent HSBC downgrade from Buy to Hold.

People also watch

Progressive Corporation

Progressive Corporation

PGR

Analysis
The Travelers Companies

The Travelers Companies

TRV

Analysis
Cincinnati Financial

Cincinnati Financial

CINF

Analysis
W. R. Berkley

W. R. Berkley

WRB

Analysis
Markel Corporation

Markel Corporation

MKL

Analysis

ALL 12-Month Price Forecast

Historical Price
Current Price $253.71
Average Target $253.71
High Target $291.77
Low Target $215.65

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $274.77 and implied upside of +8.3% versus the current price.

Average Target

$274.77

0 analysts

Implied Upside

+8.3%

vs. current price

Analyst Count

covering this stock

Price Range

$191 - $334

Analyst target range

Allstate is covered by 22 analysts, and the consensus recommendation is 'hold' with a recommendation mean of 2.6 on a scale where 1 is Strong Buy and 5 is Strong Sell, indicating a neutral-to-cautiously-optimistic stance. The average target price is $274.77, which implies approximately 8.3% upside from the current price of $253.71, a modest but positive expected return. The consensus leans neutral rather than bullish, reflecting the tension between the company's strong recent earnings and concerns about the sustainability of those results at the current valuation. The target range is wide, spanning from a low of $191.00 to a high of $334.00, a spread of $143 or roughly 75% of the low target, which signals significant disagreement among analysts about the company's trajectory. The high target of $334.00 implies roughly 31.6% upside and likely assumes continued margin expansion, benign catastrophe losses, and multiple re-rating as the market gains confidence in earnings durability, while the low target of $191.00 implies about 24.7% downside and prices in a return to elevated catastrophe losses, margin compression, or a broader sector de-rating. Institutional ratings show a clear split: JP Morgan, Evercore ISI, Mizuho, and Raymond James maintain bullish ratings (Overweight, Outperform, Outperform, and Strong Buy respectively), while Barclays remains Underweight and HSBC downgraded from Buy to Hold in July 2026, and Keefe Bruyette & Woods downgraded from Outperform to Market Perform in June 2026. This pattern of selective downgrades alongside maintained bullish ratings suggests analysts are increasingly divided on whether the stock's rally has run ahead of fundamentals, and the wide target spread combined with the recent downgrades points to elevated uncertainty and weaker conviction despite the stock's strong price performance.

Drowning in data?

Find the real signal!

Bulls vs Bears: ALL Investment Factors

The bull case currently rests on stronger near-term evidence: earnings quadrupled year-over-year, free cash flow is robust at $11.53 billion, and the trailing PE of 5.38x is extraordinarily low in absolute terms. However, the bear case raises a critical structural concern that the forward PE exceeding the trailing PE signals expected earnings normalization, meaning the market is already discounting a cyclical peak rather than mispricing sustainable earnings. The single most important tension is whether the current underwriting margins are durable or merely a temporary catastrophe-light anomaly; if the quiet catastrophe year persists, the stock is deeply undervalued, but if loss trends revert to historical norms, the earnings base could contract sharply. Analyst sentiment reflects this divide, with a 'hold' consensus and a wide $191-$334 target range, and recent downgrades from HSBC and KBW suggest growing skepticism about the rally's sustainability. On balance, the bull case has slightly stronger current evidence, but the bear case's valuation-normalization argument is the key risk that could invalidate the thesis.

Bullish

  • Earnings quadrupled year-over-year: Q1 2026 net income reached $2.458 billion versus just $595 million in Q1 2025, a roughly fourfold increase, lifting net margin from 3.66% to 14.51%. This dramatic profitability inflection reflects lower catastrophe losses and auto rate increases earning through, and it is the single most powerful fundamental driver in the current bull case.
  • Extreme trailing PE discount: The stock trades at a trailing PE of only 5.38x and a price-to-sales ratio of 0.82x, both far below typical large-cap insurer levels. Even the forward PE of 9.19x remains modest, and the PEG ratio of 0.043 suggests the market is pricing in a sharp earnings normalization that may prove too pessimistic if catastrophe losses stay contained.
  • Robust free cash flow and capital returns: Trailing-twelve-month free cash flow is $11.53 billion, with Q1 2026 alone generating $3.52 billion on $3.56 billion of operating cash flow. Management returned $614 million via buybacks and $290 million in dividends in the quarter, supported by an 11.21% payout ratio and a 2.12% dividend yield, leaving ample room for continued shareholder returns.
  • Defensive low-beta profile: With a beta of just 0.15, Allstate is roughly 85% less volatile than the broader market, and its maximum drawdown of -11.48% is far shallower than typical equity declines. This makes it an attractive holding for risk-averse or income-oriented portfolios seeking equity exposure with dampened market correlation.

Bearish

  • Forward PE exceeds trailing PE: The unusual inversion where forward PE (9.19x) is significantly higher than trailing PE (5.38x) signals that analysts expect earnings to decline from the current catastrophe-light peak. This means the market is not paying a low multiple for sustainable earnings but rather discounting a cyclical high, and if the earnings normalization is sharper than expected, the stock could de-rate further.
  • Recent analyst downgrades signal caution: HSBC downgraded Allstate from Buy to Hold in July 2026, and Keefe Bruyette & Woods downgraded from Outperform to Market Perform in June 2026. These selective downgrades alongside maintained bullish ratings indicate growing analyst division on whether the rally has run ahead of fundamentals, and the consensus 'hold' rating with a 2.6 mean reflects this cautious stance.
  • Catastrophe loss volatility threatens margins: Gross margin has been highly volatile, ranging from 24.37% in Q2 2025 to 52.96% in Q4 2025 and 45.33% in Q1 2026, driven by catastrophe-loss timing. A single severe hurricane season or elevated convective storm activity could rapidly reverse the margin expansion that underpins the entire bull thesis, as evidenced by the 2022-2023 loss years that produced negative PE ratios.
  • Stock near upper end of 52-week range: At $253.71, the stock is trading at approximately 91.5% of its 52-week range of $188.08 to $277.22, up 25.3% year-over-year and 24.5% year-to-date. This positioning near the top of the range raises the risk of profit-taking and mean reversion, especially with the 1-month change at -0.83% suggesting momentum has already cooled.

ALL Technical Analysis

Allstate is in a sustained uptrend, with the current price of $253.71 sitting roughly 25.3% above its level one year ago and about 24.5% higher year-to-date. Measured against its 52-week range of $188.08 to $277.22, the stock is trading at approximately 91.5% of that range, positioning it near the upper end and signaling strong momentum that also raises the risk of overextension. The 52-week high of $277.22 remains about 9.3% above the current price, while the 52-week low is roughly 25.9% below, underscoring how far the stock has traveled in twelve months. Recent momentum has cooled even as the longer-term trend remains intact: the 1-month change is -0.83%, a modest pullback, while the 3-month change is +14.47% and the 6-month change is +23.06%. This divergence between a slightly negative 1-month reading and a strongly positive 3-month and 1-year trend suggests a healthy consolidation or temporary pause rather than a reversal, especially since the stock still outperformed the S&P 500 over the past month, with a relative strength of +0.23% versus SPY's -1.06%. The 1-month softness likely reflects profit-taking after the July surge toward the $275 area rather than deteriorating fundamentals. Key technical support sits near the 52-week low at $188.08, with a more immediate psychological floor around the $250 level where the stock has recently stabilized, while resistance is defined by the 52-week high at $277.22. A breakout above $277.22 would confirm the uptrend's continuation and likely open the door to new highs, whereas a breakdown below $250 could accelerate a move toward the $240-$245 zone and, in a deeper correction, the 52-week low. The stock's beta of just 0.15 is a critical risk-management consideration: it implies Allstate is roughly 85% less volatile than the broader market, making it a defensive holding that tends to move independently of SPY and is well suited to lower-volatility, income-oriented portfolios. The maximum drawdown of -11.48% over the period further confirms this defensive profile, as the stock has experienced far shallower declines than the broader market.

Beta

0.15

0.15x market volatility

Max Drawdown

-11.5%

Largest decline past year

52-Week Range

$188-$277

Price range past year

Annual Return

+25.3%

Cumulative gain past year

PeriodALL ReturnS&P 500
1m-0.8%-1.6%
3m+14.5%+1.3%
6m+23.1%+13.9%
1y+25.3%+16.3%
ytd+24.5%+12.1%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ALL Fundamental Analysis

Allstate's revenue trajectory is steady and modestly growing, with the most recent quarter (Q1 2026, ended 2026-03-31) generating $16.94 billion in revenue, up 4.17% year-over-year from $16.26 billion in Q1 2025. The multi-quarter trend shows revenue oscillating in a narrow band: $16.55 billion in Q2 2025, $17.06 billion in Q3 2025, $16.59 billion in Q4 2025, and $16.94 billion in Q1 2026, indicating a mature, low-growth top line typical of a large P&C insurer where pricing and policy count, not volume expansion, drive results. The Protection Services segment contributed $915 million, a small slice of the total, confirming that the core auto and homeowners books remain the dominant revenue engines. The key takeaway is that growth is not the story here; the investment case rests on underwriting profitability and margin recovery rather than top-line acceleration. Profitability has improved dramatically, with Q1 2026 net income of $2.458 billion translating to a 14.51% net margin, up from just $595 million and a 3.66% net margin in Q1 2025, a roughly fourfold increase in earnings. Gross margin in Q1 2026 was 45.33%, though this metric is volatile for insurers due to catastrophe-loss timing, having ranged from 24.37% in Q2 2025 to 52.96% in Q4 2025. The company's operating margin of 19.80% and net margin of 15.47% are healthy for the P&C industry, and the improvement reflects the combination of lower catastrophe losses, prior-year auto rate increases earning through, and disciplined cost control. The balance sheet is conservatively managed, with a debt-to-equity ratio of just 0.2447 and a current ratio of 0.370, the latter being typical for insurers whose liabilities are dominated by reserves rather than short-term payables. Free cash flow is robust at $11.53 billion on a trailing-twelve-month basis, and Q1 2026 alone produced $3.52 billion in free cash flow on $3.56 billion of operating cash flow, demonstrating the company's ability to fund growth internally. Return on equity stands at an exceptional 33.59%, and the company returned capital aggressively in Q1 2026 through $614 million of stock repurchases and $290 million of dividends, while still growing its cash position modestly to $697 million. The low payout ratio of 11.21% and dividend yield of 2.12% leave ample room for continued buybacks and dividend growth.

Quarterly Revenue

$16.9B

2026-03

Revenue YoY Growth

+4.2%

YoY Comparison

Gross Margin

45.3%

Latest Quarter

Free Cash Flow

$11.5B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Protection Services

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ALL Overvalued?

Because Allstate is solidly profitable with trailing net income of $2.458 billion in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of just 5.38x, which is extraordinarily low in absolute terms, while the forward PE of 9.19x is meaningfully higher, implying the market expects earnings to normalize downward from the current catastrophe-light peak. This unusual inversion, where the forward multiple exceeds the trailing multiple, signals that analysts anticipate mean reversion in earnings rather than growth, a critical nuance for interpreting the valuation. Relative to the broader Financial Services sector, Allstate's trailing PE of 5.38x and forward PE of 9.19x represent a substantial discount, and its price-to-book ratio of 1.78x and price-to-sales ratio of 0.82x are also modest for a large-cap insurer. The PEG ratio of 0.043 is exceptionally low, though this figure is distorted by the cyclical earnings surge and should be treated with caution. The discount appears partly justified by the cyclical nature of the earnings peak, but the market may be underappreciating the durability of the improved underwriting margins and the benefit of higher-for-longer interest rates on investment income. Historically, Allstate's PE ratio has been volatile, ranging from negative territory during the 2022-2023 loss years to a high of 35.2x in Q2 2024 and 24.2x in Q1 2025, before compressing to the current 5.38x. The price-to-book ratio of 1.78x sits near the middle of its historical band, which has ranged from roughly 1.33x in Q4 2021 to 2.48x in Q1 2025, suggesting the stock is neither cheap nor expensive on an asset basis. The current PE near the bottom of its historical range reflects the market's skepticism that peak earnings are sustainable, creating a potential value opportunity if catastrophe losses remain contained, but also a value trap risk if the earnings surge proves temporary.

PE

5.4x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 4x~24x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

4.4x

Enterprise Value Multiple

Investment Risk Disclosure

Allstate's financial and operational risks are moderate but centered on earnings volatility rather than balance-sheet stress. The debt-to-equity ratio of 0.2447 is conservatively managed, and free cash flow of $11.53 billion on a trailing-twelve-month basis provides substantial liquidity, so solvency is not a near-term concern. However, the current ratio of 0.370, while typical for insurers whose liabilities are dominated by reserves, offers limited short-term buffer if claims payouts spike unexpectedly. The most significant financial risk is the extreme sensitivity of earnings to catastrophe losses: gross margin swung from 24.37% in Q2 2025 to 52.96% in Q4 2025, and a return to the 2022-2023 loss environment could rapidly erode the $2.458 billion quarterly net income that currently supports the valuation. Additionally, revenue growth is modest at 4.17% year-over-year, meaning the company cannot grow its way out of a margin downturn, and the forward PE of 9.19x exceeding the trailing PE of 5.38x explicitly prices in an earnings decline that could accelerate if underwriting results disappoint.

Market and competitive risks are amplified by the stock's recent rally and premium positioning. At $253.71, the stock trades at roughly 91.5% of its 52-week range and has risen 25.3% over the past year, creating vulnerability to profit-taking or sector rotation. The beta of 0.15 means the stock moves largely independently of the broader market, which is a defensive advantage in downturns but also means it will not benefit from broad market rallies and could underperform if capital rotates into higher-beta growth sectors. Competitive pressure from direct-to-consumer insurers and regional underwriters could constrain pricing power, particularly in personal auto where Allstate's exclusive-agent model carries higher distribution costs than digital-native competitors. Regulatory risk is also material: auto rate increases that drove the margin recovery could face pushback from state insurance commissioners if consumer advocacy intensifies, and any adverse regulatory ruling could cap further rate actions. Recent news highlights the 'quiet catastrophe year' as a key earnings driver, but this also means the stock is vulnerable to any negative weather-related headlines that break the narrative.

The worst-case scenario for Allstate would be a confluence of a severe hurricane season, a reversal in auto rate adequacy, and a broader sector de-rating that compresses the multiple from already-low levels. In this scenario, the stock could retest its 52-week low of $188.08, representing approximately 25.9% downside from the current price of $253.71, and the analyst low target of $191.00 implies a similar 24.7% decline. If catastrophe losses returned to 2022-2023 levels, the company could swing to a quarterly loss, and the trailing PE would become meaningless or negative, forcing the market to value the stock on price-to-book, which at 1.78x could compress toward the historical low of 1.33x seen in Q4 2021, implying a price closer to $190. A realistic adverse scenario would see the stock fall 20-26% to the $188-$191 range, and a more extreme outcome involving multiple years of elevated losses and regulatory rate suppression could push it below $180, representing a loss of roughly 29% from current levels.